[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regencell Bioscience Holdings Ltd (RGC)

Regencell Bioscience Holdings Ltd (RGC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,957,876
  • Shares Outstanding, K 494,489
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,580 K
  • EBIT $ 0 M
  • EBITDA $ -4 M
  • 60-Month Beta 1.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 126.74% (+12.07%)
  • Historical Volatility 73.47%
  • IV Percentile 15%
  • IV Rank 12.56%
  • IV High 310.58% on 07/03/25
  • IV Low 100.32% on 10/20/25
  • Expected Move (DTE 13) 1.70 (8.39%)
  • Put/Call Vol Ratio 0.80
  • Today's Volume 445
  • Volume Avg (30-Day) 476
  • Put/Call OI Ratio 1.11
  • Today's Open Interest 5,680
  • Open Int (30-Day) 5,716
  • Expected Range 18.57 to 21.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/17
See More
  • Average Estimate $0.34
  • Number of Estimates 6
  • High Estimate $0.39
  • Low Estimate $0.30
  • Prior Year $0.33
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.70 +1.78%
on 06/05/26
32.00 -37.34%
on 05/07/26
-7.22 (-26.48%)
since 05/05/26
3-Month
19.70 +1.78%
on 06/05/26
40.00 -49.87%
on 04/01/26
-4.16 (-17.18%)
since 03/05/26
52-Week
9.39 +113.53%
on 07/02/25
83.60 -76.02%
on 06/16/25
+3.60 (+21.91%)
since 06/05/25

Most Recent Stories

More News
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors Should Contact SueWallSt

The Red Flags: What Insiders Allegedly Knew Before Shareholders Did — Regencell's $14 Billion Valuation Rested on Zero Revenue and Twelve Employees While Market Manipulation Vulnerability Went...

RGC : 20.20 (-8.84%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC

NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC)...

RGC : 20.20 (-8.84%)
RGC DEADLINE: Levi & Korsinsky Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action Deadline

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRA — RGC Investors Who Lost Money During the Class Period Have Until June 23, 2026 to Seek Appointment

RGC : 20.20 (-8.84%)
Regencell Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

NEW YORK , June 2, 2026 /PRNewswire/ --

RGC : 20.20 (-8.84%)
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky

Key Dates and Disclosure Events Shareholders Need to Know: How Regencell's Stock Surged 48,650% on No Fundamental News Before a DOJ Subpoena Wiped Out $3.09 Per Share

RGC : 20.20 (-8.84%)
RGC Shareholder Alert: Regencell Bioscience Holdings Limited Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

NEW YORK , June 2, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Regencell Bioscience Holdings Limited (NASDAQ: RGC).

RGC : 20.20 (-8.84%)
Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , June 1, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit...

RGC : 20.20 (-8.84%)
Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , May 29, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

RGC : 20.20 (-8.84%)
Regencell Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

NEW YORK , May 28, 2026 /PRNewswire/ --

RGC : 20.20 (-8.84%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC

NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC)...

RGC : 20.20 (-8.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Regencell Bioscience Holdings Limited is an early-stage bioscience company which focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum...

See More

Key Turning Points

3rd Resistance Point 25.63
2nd Resistance Point 24.79
1st Resistance Point 23.48
Last Price 20.20
1st Support Level 21.32
2nd Support Level 20.48
3rd Support Level 19.17

See More

52-Week High 83.60
Fibonacci 61.8% 55.25
Fibonacci 50% 46.49
Fibonacci 38.2% 37.74
Last Price 20.20
52-Week Low 9.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.